Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ASPH | Q12797 | 2/20 | 0.41 |
| ▸ | RIOX2 | Q8IUF8 | 2/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 15/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765994 | 0.92 | ELANE (0.46) | KDM4EASPHRIOX2KDM8ELANE | |
| SCHEMBL30765457 | 0.91 | ELANE (0.43) | KDM4EASPHRIOX2KDM8ELANE | |
| SCHEMBL30765773 | 0.90 | ELANE (0.41) | KDM4EASPHRIOX2KDM8ELANE | |
| SCHEMBL23460649 | 0.86 | ELANE (0.47) | KDM4EASPHRIOX2KDM8ELANE | |
| SCHEMBL30765644 | 0.86 | KDM4E (0.42) | KDM4EASPHRIOX2KDM8ALDH1A1 | |
| SCHEMBL30765980 | 0.84 | ELANE (0.39) | KDM4EASPHRIOX2KDM8ELANE | |
| SCHEMBL30765868 | 0.84 | F2 (0.42) | KDM4EASPHRIOX2KDM8ELANE | |
| SCHEMBL30765501 | 0.83 | ELANE (0.44) | KDM4EELANEALDH1A1F2EGLN1 | |
| SCHEMBL30765914 | 0.83 | ELANE (0.39) | KDM4EASPHRIOX2KDM8ELANE | |
| SCHEMBL30765490 | 0.83 | ELANE (0.39) | KDM4EASPHRIOX2KDM8ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |